Innovating IVF with
Our New Test
Built on 20 years of proteomics and metabolomics research, we are proud to introduce our proprietary non-invasive blastocyst selection test – aimed at reducing time to pregnancy in IVF treatments.
Embryologists and clinicians will now have an essential tool to optimize decision-making and bring patients closer to success—faster than ever before.
Join us in setting a new standard for fertility care, where innovation drives results.
INTRODUCING
PMT-BC
Pre-implantation Metabolomic Test – Blastocyst Competency
PMT-BC is a highly effective, simple, non-invasive test in spent
blastocyst media (SBM) for embryo selection in IVF treatment –
it estimates the relative probability of implantation for each blastocyst
1. Blastocyst and embryo screening selection tool (BESST): an ultrafast non-invasive embryo selection test for use immediately prior to embryo transfer, Poster session| Volume 112, ISSUE 3, SUPPLEMENT, e276, September 2019
2. Pregnancy confirmed by b-hCG test 2 weeks after blastocyst transfer
Note: BESST has changed name to PMT-BC.
47% higher transfer to pregnancy (TTP) success rate using PMT-BC vs control group 1,2
